AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $41.45.

ANAB has been the subject of several research analyst reports. Wedbush restated an “outperform” rating and issued a $40.00 target price (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Guggenheim cut their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. JPMorgan Chase & Co. decreased their target price on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Wells Fargo & Company dropped their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Finally, BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $14.21 on Monday. The firm has a market capitalization of $432.40 million, a PE ratio of -2.34 and a beta of -0.02. The business’s fifty day moving average price is $18.67 and its 200 day moving average price is $28.13. AnaptysBio has a 12 month low of $12.51 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, equities analysts anticipate that AnaptysBio will post -6.02 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 6,646 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were purchased at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the purchase, the director now directly owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 33.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. grew its stake in shares of AnaptysBio by 2.0% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after purchasing an additional 43,598 shares during the period. Ensign Peak Advisors Inc boosted its holdings in AnaptysBio by 74.4% during the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after buying an additional 32,313 shares in the last quarter. Point72 Asset Management L.P. grew its position in AnaptysBio by 202.8% during the third quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock worth $1,816,000 after buying an additional 36,300 shares during the period. Victory Capital Management Inc. increased its holdings in AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after buying an additional 206,750 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after acquiring an additional 168,813 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.